Role of adrenal androgen in prostate cancer
Mizokami, A.; Izumi, K.; Namiki, M.
Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 99-105
2016
ISSN/ISBN: 0047-1852 PMID: 27344711 Document Number: 686194
Document emailed within 1 workday
Related Documents
Jenster, G. 1999: The role of the androgen receptor in the development and progression of prostate cancer Seminars in Oncology 26(4): 407-421Pettaway, C.A. 1999: Racial differences in the androgen/androgen receptor pathway in prostate cancer Journal of the National Medical Association 91(12): 653-660
Bastos, D.A.; Dzik, C.; Rathkopf, D.; Scher, H.I. 2014: Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer Oncology 28(8): 693-699
Izbicka, E.; MacDonald, J.R.; Davidson, K.; Lawrence, R.A.; Gomez, L.; Von Hoff, D.D. 1999: 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells Anticancer Research 19(2a): 1285-1291
Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; Kallioniemi, O.P. 1997: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Research 57(2): 314-319
Nakai, Y.; Tsujimura, A.; Nonomura, N. 2011: Prostate cancer--the role of adrenal steroids Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 5): 112-116
Amler, L.C.; Agus, D.B.; LeDuc, C.; Sapinoso, M.L.; Fox, W.D.; Kern, S.; Lee, D.; Wang, V.; Leysens, M.; Higgins, B.; Martin, J.; Gerald, W.; Dracopoli, N.; Cordon-Cardo, C.; Scher, H.I.; Hampton, G.M. 2000: Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1 Cancer Research 60(21): 6134-6141
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Gao, J.; Isaacs, J.T. 1998: Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells Cancer Research 58(15): 3299-3306
Jarrard, D.F.; Kinoshita, H.; Shi, Y.; Sandefur, C.; Hoff, D.; Meisner, L.F.; Chang, C.; Herman, J.G.; Isaacs, W.B.; Nassif, N. 1998: Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells Cancer Research 58(23): 5310-5314
Beuzeboc, P.; Richaud, P. 2003: Androgen replacement therapy and prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(5 Suppl 2: 1276-1277
Kagebayashi, Y.; Ozono, S.; Takashima, K.; Yoshikawa, M.; Hayashi, Y.; Kaneko, Y.; Maruyama, Y.; Hirao, Y.; Okajima, E. 1997: Total androgen blockade for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 43(3): 197-201
Roth, B.J. 1999: Androgen-independent prostate cancer: not so chemorefractory after all Seminars in Oncology 26(6 Suppl 18: 43-50
Rentsch, C.A.; Aebersold, D.M.; Merz, V.; Studer, U.E. 2005: Cancer of the prostate: importance of androgen deprivation and radiotherapy Revue Medicale Suisse 1(19): 1303-1306
Shiota, M.; Yokomizo, A.; Naito, S.; Fujimoto, N. 2011: Alteration of androgen receptor cofactor in prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 5): 108-111
Kirby, R.S. 1996: Maximal androgen blockade (MAB) for the treatment of prostate cancer British Journal of Clinical Practice 50(5): 287
Roux, C. 2003: Osteoporosis due to androgen suppression therapy in men with prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(2 Suppl 1: 24-27
Magi-Galluzzi, C.; Xu, X.; Hlatky, L.; Hahnfeldt, P.; Kaplan, I.; Hsiao, P.; Chang, C.; Loda, M. 1997: Heterogeneity of androgen receptor content in advanced prostate cancer Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 10(8): 839-845
Vis, A.é N.; van Moorselaar, R.J.A. 2019: Androgen receptor inhibitors in prostate cancer: new drugs, but for which patient? Nederlands Tijdschrift Voor Geneeskunde 163
Buyyounouski, M.K. 2010: Androgen deprivation therapy in high-risk prostate cancer Oncology 24(9): 806; 809